NCT06482905 - Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 4, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

June 30, 2027

Conditions

High-grade GliomaWHO Grade Ⅳ Glioma

Interventions

BIOLOGICAL

Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103

"Safety Run-In: Dose:6×10\^7 CAR+ T cells~Cohort A Single delivery route(Multi-dose)、Cohort B Dual delivery route(Multi-dose)： 3+3 dose escalation design： Dose Level 1: 6×10\^7 CAR+ T cells Dose Level 2: 1.5×10\^8 CAR+ T cells Dose Level 3: 2.5×10\^8 CAR+ T cells"

Trial Locations (4)

32224

NOT_YET_RECRUITING

Mayo Clinic in Florida, Jacksonville

55905

NOT_YET_RECRUITING

Mayo Clinic in Rochester, Rochester

85054

NOT_YET_RECRUITING

Mayo Clinic in Arizona, Phoenix

100730

RECRUITING

Beijing Tiantan Hospital, Beijing